UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
| FORM 8-K |
| |
| CURRENT REPORT |
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
| |
| Date of Report (Date of earliest event reported):March 26, 2020 |
| |
| AIKIDO PHARMA INC. |
| (Exact name of registrant as specified in its charter) |
| Delaware | 000-05576 | 52-0849320 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| One Rockefeller Plaza, 11th Floor, New York, NY | 10020 |
| (Address of principal executive offices) | (Zip Code) |
| |
| Registrant’s telephone number, including area code: (703) 992-9325 |
| |
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.0001 par value | AIKI | The Nasdaq Capital Market |
| Item 5.08 | Shareholder Director Nominations. |
AIkido Pharma, Inc., a Delaware corporation (the “Company”), is announcing today that the Board of Directors (the “Board”) of the Company has decided to hold the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) on or around December 1, 2020. The Company will announce the Annual Meeting’s definitive date, time and related deadlines after a final decision has been made. The Company will subsequently file and mail proxy materials as required.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | AIKIDO PHARMA INC. |
| | |
| | By: | /s/ Anthony Hayes |
| | Name: Title: | Anthony Hayes
Chief Executive Officer |
Dated: March 26, 2020
